TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience Corporation stocks have been trading up by 7.1 percent following highly positive sentiment around its latest developments.

Weekly Update Sep 14 – Sep 18, 2026: On Saturday, September 19, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.1%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Twist Bioscience occupies a differentiated position in synthetic DNA and antibody discovery, with strong 52% gross margins and nearly 10% three‑year revenue CAGR off a $377M base, but remains structurally loss‑making (EBIT margin ~‑32%, ROE ~‑30%). Cash burn is material: Q3 free cash flow was ‑$8.6M despite positive $1.1M operating cash flow largely driven by $18M stock‑based comp. Balance sheet risk is contained near term, with current ratio 2.7 and modest leverage (total debt/equity 0.21).

The stock is in a powerful short‑term uptrend: from $133.41 close on 9/14 to $166.60 on 9/18, with successive higher highs and no material intraday reversals, indicating aggressive buying following the news flow. The 9/17–9/18 range ($155–167) is the new control zone; $155 emerges as first meaningful support and a clear risk‑management line. For active traders, pullbacks toward $155 with stabilizing intraday volume offer high‑reward entries, targeting a retest and extension above $170.

Lilly TuneLab and Anthropic mini‑binder work firmly position Twist at the intersection of synthetic biology and AI drug discovery, a structural growth vector well ahead of the broader Healthcare and Diagnostics & Screening groups. The Leerink PT hike to $160 and UBS’s $144 initiation validate institutional demand for the AI narrative despite ongoing losses. I see the risk‑reward skewed favorably: accumulate on dips toward $155 support, with a 6–12 month upside target zone of $185–$200 and technical resistance beginning near $175.

Quick Financial Overview

Twist Bioscience Corporation is trading in a strong upswing, with the weekly chart showing a move from $133.41 to $166.60 over the recent data window. That is a sharp multi-day leg higher, reinforced by intraday action where price ran from an open near $158 to a session high above $167 before closing just under that high. For short-term traders, that is classic momentum behavior: buyers in control, shallow intraday pullbacks, and a close near the top of the day’s range.

The Lilly TuneLab agreement is driving this surge, as TWST locks its antibody characterization workflows directly into Eli Lilly’s AI/ML drug discovery platform. Multiple reports tie the share price pop, including gains of more than 4% on one session, to this AI collaboration. On the Street side, Leerink lifting its price target from $120 to $160 with an Outperform call, and UBS coming in at $144 with a Neutral, both anchor expectations well above prior averages and help explain why traders are willing to chase strength.

Under the hood, Twist Bioscience generated about $376.57M in revenue over the trailing period, with a healthy 52% gross margin but deep negative profitability metrics, including an EBIT margin near -31.8% and returns on equity around -29%. The latest quarterly report (period ending 2026/06/30) shows $118.38M in revenue but a net loss of roughly $35.05M and EBITDA of about -$27.96M, although operating cash flow turned slightly positive at $1.12M. Balance sheet strength is reasonable for a high-growth name, with a current ratio of 2.7 and total debt to equity at 0.21, but valuation is rich, with price-to-sales around 23.89 and price-to-book over 23, which helps explain why some analysts stay cautious even as they set high absolute targets.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks